BARCELONA, SPAIN — A new "deescalation" regimen of dual antiplatelet therapy post-ACS—which involves switching from prasugrel (Effient, Lilly/Daiichi-Sankyo) to clopidogrel in certain patients guided ...
March 6, 2009 (Munich, Germany) — More evidence that patients with a low platelet responsiveness to clopidogrel have an increased risk of stent thrombosis has come from a new study, with the ...
Even relatively mild anemia predicts high residual platelet reactivity following percutaneous coronary intervention (PCI) in patients pre-treated with clopidogrel, according to data published online ...
Federal drug regulators added a boxed warning to the anti-blood clotting medicine Plavix, alerting physicians and patients that it could be less effective in people who cannot metabolize the pill ...
Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...
The somewhat conflicting results of CURRENT-OASIS 7 have inspired new correspondence in the January 22, 2011, issue of the Lancet that question how best to implement the study’s findings regarding ...
ORLANDO, Fla. -- A new blood thinner proved better than Plavix, one of the world's top-selling drugs, at preventing heart problems after procedures to open clogged arteries, doctors reported Sunday.
ORLANDO -- The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds. The effect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results